JPWO2006049160A1 - 血液接触材料の改質方法、及び顆粒球活性化が抑制された血液接触材料 - Google Patents
血液接触材料の改質方法、及び顆粒球活性化が抑制された血液接触材料 Download PDFInfo
- Publication number
- JPWO2006049160A1 JPWO2006049160A1 JP2006542397A JP2006542397A JPWO2006049160A1 JP WO2006049160 A1 JPWO2006049160 A1 JP WO2006049160A1 JP 2006542397 A JP2006542397 A JP 2006542397A JP 2006542397 A JP2006542397 A JP 2006542397A JP WO2006049160 A1 JPWO2006049160 A1 JP WO2006049160A1
- Authority
- JP
- Japan
- Prior art keywords
- contact material
- blood contact
- blood
- tryptophan
- polyanionic compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 84
- 239000008280 blood Substances 0.000 title claims abstract description 84
- 239000000463 material Substances 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 50
- 210000003714 granulocyte Anatomy 0.000 title claims abstract description 21
- 230000004913 activation Effects 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 40
- 229960000633 dextran sulfate Drugs 0.000 claims abstract description 14
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000003100 immobilizing effect Effects 0.000 claims abstract description 6
- 238000000746 purification Methods 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 2
- 238000002407 reforming Methods 0.000 claims 1
- 230000009471 action Effects 0.000 abstract description 9
- 239000011324 bead Substances 0.000 description 27
- 229920002678 cellulose Polymers 0.000 description 25
- 239000001913 cellulose Substances 0.000 description 25
- 108010028275 Leukocyte Elastase Proteins 0.000 description 15
- 102000016799 Leukocyte elastase Human genes 0.000 description 15
- 125000000524 functional group Chemical group 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229960004799 tryptophan Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 7
- 229920002125 Sokalan® Polymers 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical group OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000004584 polyacrylic acid Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229950003937 tolonium Drugs 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 5
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- -1 cyanogen halide Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 3
- 229940005642 polystyrene sulfonic acid Drugs 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 102000003896 Myeloperoxidases Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 229920000805 Polyaspartic acid Polymers 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229920001284 acidic polysaccharide Polymers 0.000 description 2
- 150000004805 acidic polysaccharides Chemical class 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003617 erythrocyte membrane Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 108010064470 polyaspartate Proteins 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- UDQCRUSSQAXPJY-VIFPVBQESA-N (2s)-2-amino-3-(1h-indol-3-yl)propan-1-ol Chemical compound C1=CC=C2C(C[C@@H](CO)N)=CNC2=C1 UDQCRUSSQAXPJY-VIFPVBQESA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- IGKMJWPWSFSLDV-UHFFFAOYSA-N 1,4-dimethylcyclohexa-2,4-diene-1-carbaldehyde Chemical compound CC1=CCC(C)(C=O)C=C1 IGKMJWPWSFSLDV-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical group FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 238000004438 BET method Methods 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920000045 Dermatan sulfate Chemical group 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000004018 acid anhydride group Chemical group 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical group CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- DABYEOZXRSTEGL-NSHDSACASA-N ethyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)OCC)=CNC2=C1 DABYEOZXRSTEGL-NSHDSACASA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- KCUNTYMNJVXYKZ-JTQLQIEISA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-JTQLQIEISA-N 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- DABYEOZXRSTEGL-UHFFFAOYSA-N racemic tryptophan ethyl ester Natural products C1=CC=C2C(CC(N)C(=O)OCC)=CNC2=C1 DABYEOZXRSTEGL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/08—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- External Artificial Organs (AREA)
Abstract
Description
ジェイ・ベーラー(J.Boehler)ら、ネフロロジー・ダイアリシス・トランスプランテーション(Nephrology Dialysis Transplantation)第8巻、1359〜1365頁、1993年 樋口ら、人工臓器 26巻4号:835〜839頁、1997年 エス・エス・シュミットマン(S.S.Schmidtmann)ら、ネフロロジー・ダイアリシス・トランスプランテーション(Nephrology Dialysis Transplantation)第5巻、600〜603頁、1990年
本発明者らは、ポリアニオン性化合物の固定化量、並びにトリプトファン誘導体の固定化量と、血液接触時の顆粒球活性化の程度につき鋭意検討した結果、驚くべきことに、ポリアニオン性化合物の固定化量を表面積1m2当たり6.4nmol以上96.2nmol以下とし、かつTR/PA比を1以上70以下に制御することにより、血中の顆粒球活性化の低減効果があることを見いだした。
平均粒径約450μmのセルロースビーズ100mL(湿潤時の沈降体積)に水22ml、4N NaOH水溶液34mlおよびエピクロロヒドリン33mlを加え、40℃で2時間攪拌して反応させた。反応後ビーズを水で十分洗浄してエポキシ化セルロースビーズを得た。
また、トリプトファン固定化量は、改質セルロースビーズの窒素含有量から求めた。すなわち1mlの改質セルロースビーズを水で充分洗浄した後、60℃で6時間以上減圧乾燥した後、微量全窒素分析装置により定量した。その結果、改質セルロースビーズのトリプトファン固定化量は435.0nmol/m2であった。
実施例1の改質前セルロースビーズを実施例1のポリプロピレンチューブに0.5ml計量し、生理食塩液で膨潤させた後、これに実施例1と同一の健常人血液3mlを添加し、37℃で30minバッチ接触させ、バッチ接触前後の顆粒球エラスターゼ濃度を測定した。その結果、接触後の顆粒球エラスターゼ濃度は134(μg/L)となった。
Claims (12)
- 血液接触材料にポリアニオン性化合物およびトリプトファン誘導体を固定化することにより、顆粒球活性化を抑制することを特徴とする血液接触材料の改質方法。
- ポリアニオン性化合物の固定化量が表面積1m2当たり6.4nmol以上96.2nmol以下で、かつトリプトファン誘導体の固定化量とポリアニオン性化合物固定化量とのモル比が1以上70以下である血液接触材料の改質方法。
- ポリアニオン性化合物がデキストラン硫酸である請求項1あるいは2記載の血液接触材料の改質方法。
- トリプトファン誘導体がトリプトファンである請求項1から3のいずれかに記載の血液接触材料の改質方法。
- 血液接触材料がヒドロキシル基を有する高分子化合物よりなる請求項1から4のいずれかに記載の血液接触材料の改質方法。
- ポリアニオン性化合物およびトリプトファン誘導体を固定化してなる顆粒球活性化が抑制された血液接触材料であって、ポリアニオン性化合物の固定化量が表面積1m2当たり6.4nmol以上96.2nmol以下、かつトリプトファン誘導体の固定化量とポリアニオン性化合物固定化量とのモル比が1以上70以下である血液接触材料。
- ポリアニオン性化合物がデキストラン硫酸である請求項6記載の血液接触材料。
- トリプトファン誘導体がトリプトファンである請求項6または7記載の血液接触材料。
- 血液接触材料がヒドロキシル基を有する高分子化合物よりなる請求項6から8のいずれかに記載の血液接触材料。
- 請求項6から9のいずれかに記載の血液接触材料を用いた血液接触回路。
- 請求項6から9のいずれかに記載の血液接触材料を用いた体内留置器具。
- 請求項6から9のいずれかに記載の血液接触材料を用いた血液浄化装置。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006542397A JP5036315B2 (ja) | 2004-11-05 | 2005-11-01 | 血液接触材料の改質方法、及び顆粒球活性化が抑制された血液接触材料 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004322019 | 2004-11-05 | ||
JP2004322019 | 2004-11-05 | ||
PCT/JP2005/020099 WO2006049160A1 (ja) | 2004-11-05 | 2005-11-01 | 血液接触材料の改質方法、及び顆粒球活性化が抑制された血液接触材料 |
JP2006542397A JP5036315B2 (ja) | 2004-11-05 | 2005-11-01 | 血液接触材料の改質方法、及び顆粒球活性化が抑制された血液接触材料 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2006049160A1 true JPWO2006049160A1 (ja) | 2008-05-29 |
JP5036315B2 JP5036315B2 (ja) | 2012-09-26 |
Family
ID=36319165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006542397A Active JP5036315B2 (ja) | 2004-11-05 | 2005-11-01 | 血液接触材料の改質方法、及び顆粒球活性化が抑制された血液接触材料 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070270523A1 (ja) |
EP (1) | EP1818066A4 (ja) |
JP (1) | JP5036315B2 (ja) |
WO (1) | WO2006049160A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5374064B2 (ja) * | 2008-03-31 | 2013-12-25 | 株式会社カネカ | 血液接触材料の改質方法、及び補体活性化が抑制された血液接触材料 |
JP5318586B2 (ja) * | 2009-01-08 | 2013-10-16 | 株式会社カネカ | 血液適合性に優れた免疫グロブリン吸着材、及び吸着器 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6090039A (ja) * | 1983-10-21 | 1985-05-21 | Asahi Chem Ind Co Ltd | 血液浄化吸着体 |
WO2001074420A1 (fr) * | 2000-04-05 | 2001-10-11 | Toray Industries, Inc. | Adsorbants pour proteines de la famille hmg et colonne de purification de liquide organique |
WO2002060512A1 (fr) * | 2001-01-30 | 2002-08-08 | Kaneka Corporation | Processeur de liquide organique permettant une hemoperfusion directe |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57122875A (en) * | 1981-01-22 | 1982-07-30 | Asahi Chemical Ind | Immunity adsorbing material and adsorbing device |
US4432871A (en) * | 1981-01-22 | 1984-02-21 | Asahi Kasei Kogyo Kabushiki Kaisha | Immune adsorbent, adsorbing device and blood purifying apparatus |
JPS61187866A (ja) * | 1985-02-14 | 1986-08-21 | 理研ビタミン株式会社 | 新規な医療用被覆材 |
NO931809L (no) * | 1993-05-19 | 1994-11-21 | Norsk Hydro As | Hemofilter |
JP4578405B2 (ja) * | 2003-05-08 | 2010-11-10 | 株式会社カネカ | 全血処理が可能な低密度リポ蛋白およびフィブリノーゲンの吸着材、及び吸着器 |
-
2005
- 2005-11-01 US US11/718,386 patent/US20070270523A1/en not_active Abandoned
- 2005-11-01 EP EP05800319A patent/EP1818066A4/en not_active Withdrawn
- 2005-11-01 JP JP2006542397A patent/JP5036315B2/ja active Active
- 2005-11-01 WO PCT/JP2005/020099 patent/WO2006049160A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6090039A (ja) * | 1983-10-21 | 1985-05-21 | Asahi Chem Ind Co Ltd | 血液浄化吸着体 |
WO2001074420A1 (fr) * | 2000-04-05 | 2001-10-11 | Toray Industries, Inc. | Adsorbants pour proteines de la famille hmg et colonne de purification de liquide organique |
WO2002060512A1 (fr) * | 2001-01-30 | 2002-08-08 | Kaneka Corporation | Processeur de liquide organique permettant une hemoperfusion directe |
Also Published As
Publication number | Publication date |
---|---|
EP1818066A1 (en) | 2007-08-15 |
WO2006049160A1 (ja) | 2006-05-11 |
JP5036315B2 (ja) | 2012-09-26 |
EP1818066A4 (en) | 2011-08-31 |
US20070270523A1 (en) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guo et al. | Adsorptive separation of hemoglobin by molecularly imprinted chitosan beads | |
JP4578405B2 (ja) | 全血処理が可能な低密度リポ蛋白およびフィブリノーゲンの吸着材、及び吸着器 | |
JPH0144725B2 (ja) | ||
JPH08117333A (ja) | 血液灌流用の改良された親和性担体 | |
Dang et al. | Heparin as a molecular spacer immobilized on microspheres to improve blood compatibility in hemoperfusion | |
CN113908328A (zh) | 一种基于海藻酸钠、纳晶纤维素的抗菌止血多孔微球 | |
JP5036315B2 (ja) | 血液接触材料の改質方法、及び顆粒球活性化が抑制された血液接触材料 | |
JP5374064B2 (ja) | 血液接触材料の改質方法、及び補体活性化が抑制された血液接触材料 | |
CN109248668B (zh) | 用于血液体外循环去除ldl的吸附剂及其制备方法和灌流器 | |
JP3285441B2 (ja) | 血管閉塞性疾患血漿の血漿粘度低下用吸着材及び血漿粘度低下装置 | |
Uzun et al. | Poly (hydroxyethyl methacrylate) based affinity membranes for in vitro removal of anti-dsDNA antibodies from SLE plasma | |
JPH02149341A (ja) | 血清アミロイドp蛋白用吸着体 | |
WO2006049163A1 (ja) | 全血処理が可能なブラジキニンを発生させる体液処理材 | |
JP3157026B2 (ja) | 血液浄化用吸着材 | |
He et al. | Study of the oxidation of crosslinked β-cyclodextrin polymer and its use in the removal of urea. I | |
Hüseynli et al. | Fab fragment immobilized immunoaffinity cryogels as a tool for human serum albumin purification: Characterization of Fab immobilized cryogels | |
JP2016053144A (ja) | 吸水性樹脂粒子、吸水性樹脂粒子の製造方法及び吸収体 | |
JP2665526B2 (ja) | β2−ミクログロブリンの吸着材 | |
JPH06233816A (ja) | 血液浄化吸着材 | |
JP5214857B2 (ja) | 多孔質基材 | |
JP2001300308A (ja) | エンドトキシン吸着材 | |
JP4141224B2 (ja) | 低密度リポ蛋白およびフィブリノーゲンの吸着材、及びその吸着器 | |
JP5920888B2 (ja) | ネコ尿中コーキシン除去材料 | |
JPH105330A (ja) | 細胞由来放出因子の吸着体、それを用いる吸着除去装置および吸着除去方法 | |
JPH06233815A (ja) | 血液浄化吸着材 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081001 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120308 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120626 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120703 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150713 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5036315 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150713 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |